Consensus Statement on the Management of Patients With Asymptomatic Hyperuricemia in General Medical Practice

Abstract

Hyperuricemia is a condition characterized by an increase of serum uric acid level above 360 µmol/L. It is known that high serum uric acid levels are not only the condition for the etiopathogenesis of gout but also an important risk factor for the development and progression of cardiovascular diseases, kidney and liver pathologies, type 2 diabetes, and others. This makes hyperuricemia a relevant issue in general therapeutic practice. Despite extensive evidence on the negative role of hyperuricemia in many internal organ diseases, the management strategy for patients with asymptomatic hyperuricemia in real clinical practice remains a subject of debate.

This resolution represents an interdisciplinary consensus of experts from Commonwealth of Independent States, based on current evidence-based medicine data and proprietary registries. The proposed algorithm emphasizes the importance of a personalized approach to the treatment of hyperuricemia, taking into account the severity of comorbid conditions and the level of cardiovascular risk. Step-by-step recommendations are provided for general practitioners, family doctors, and a wide range of specialists in both non-pharmacological and pharmacological urate-lowering therapy. These guidelines aim to improve the quality of medical care for patients at high risk of socially significant diseases occurring together with asymptomatic hyperuricemia.

Keywords

hyperuricemia / cardiovascular risk / cardiovascular diseases / noncommunicable diseases / osteoarthritis / chronic kidney disease / rheumatoid arthritis / urate-lowering therapy / prevention

References

[1] Shalnova SA, Deev AD, Artamonov GV, et al. Hyperuricemia and its correlates in the Russian population (results of ESSE-RF epidemiological study). Rational Pharmacotherapy in Cardiology. 2014;10(2):153–159. EDN: SCOUHN doi: 10.20996/1819-6446-2014-10-2-153-159

[2] Шальнова С.А., Деев А.Д., Артамонова Г.В., и др. Гиперурикемия и ее корреляты в Российской популяции (результаты эпидемиологического исследования ЭССЕ-РФ) // Рациональная фармакотерапия в кардиологии. 2014. Т. 10, № 2. С.153–159. EDN: SCOUHN doi: 10.20996/1819-6446-2014-10-2-153-159

[3] Chen-Xu M, Yokose C, Rai SK, et al. Contemporary prevalence of gout and hyperuricemia in the united states and decadal trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol. 2019;71(6):991–999. doi: 10.1002/art.40807

[4] Chen-Xu M., Yokose C., Rai S.K., et al. Contemporary prevalence of gout and hyperuricemia in the united states and decadal trends: The National Health and Nutrition Examination Survey, 2007-2016 // Arthritis Rheumatol. 2019. Vol. 71, N 6. P. 991–999. doi: 10.1002/art.40807

[5] FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6):744–760. doi: 10.1002/acr.24180

[6] FitzGerald J.D., Dalbeth N., Mikuls T., et al. 2020 American College of Rheumatology Guideline for the Management of Gout // Arthritis Care Res (Hoboken). 2020. Vol. 72, N 6. P. 744–760. doi: 10.1002/acr.24180

[7] Neilson J, Bonnon A, Dickson A, et al. Gout: diagnosis and management-summary of NICE guidance. BMJ. 2022;378:o1754. doi: 10.1136/bmj.o1754

[8] Neilson J., Bonnon A., Dickson A., et al. Gout: diagnosis and management-summary of NICE guidance // BMJ. 2022. Vol. 378. P. o1754. doi: 10.1136/bmj.o1754

[9] Hui M, Carr A, Cameron S, et al. The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford). 2017;56(7):1246. doi: 10.1093/rheumatology/kex250

[10] Hui M., Carr A., Cameron S., et al. The British Society for Rheumatology Guideline for the Management of Gout // Rheumatology (Oxford). 2017. Vol. 56, N 7. P. 1246. doi: 10.1093/rheumatology/kex250

[11] Drapkina OM, Mazurov VI, Martynov AI, et al. “Focus on hyperuricemia”. The resolution of the Expert Council. Cardiovascular Therapy and Prevention. 2023;22(4):77–84. EDN: KRCKAU doi: 10.15829/1728-8800-2023-3564

[12] Драпкина О.М., Мазуров В.И., Мартынов А.И., и др. «В фокусе гиперурикемия». Резолюция Cовета экспертов // Кардиоваскулярная терапия и профилактика. 2023. Т. 22, № 4. С. 77–84. EDN: KRCKAU doi: 10.15829/1728-8800-2023-3564

[13] Bursill D, Taylor WJ, Terkeltaub R, et al. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann Rheum Dis. 2019;78(11):1592–1600. doi: 10.1136/annrheumdis-2019-215933

[14] Bursill D., Taylor W.J., Terkeltaub R., et al. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout // Ann Rheum Dis. 2019. Vol. 78, N 11. P. 1592–1600. doi: 10.1136/annrheumdis-2019-215933

[15] Chazova IE, Zhernakova YuV, Kislyak OA, et al. Consensus on patients with hyperuricemia and high cardiovascular risk treatment: 2022. Systemic Hypertension. 2022;19(1):5–22. EDN: HSKPCZ doi: 10.38109/2075-082X-2022-1-5-22

[16] Чазова И.Е., Жернакова Ю.В., Кисляк О.А., и др. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском: 2022 // Системные гипертензии. 2022. Т. 19, № 1. С. 5–22. EDN: HSKPCZ doi: 10.38109/2075-082X-2022-1-5-22

[17] Eliseev MS, Vykhodets IТ, Kruglova IV, et al. Prevalence of hyperuricemia in professional athletes and its role in the genesis of various pathological conditions and metabolic disturbances. Modern Rheumatology Journal. 2018;12(3):82–88. EDN: YOCLTN doi: 10.14412/1996-7012-2018-3-82-88

[18] Елисеев М.С., Выходец И.Т., Круглова И.В., и др. Распространенность гиперурикемии у профессиональных спортсменов и ее роль в генезе различных патологических состояний и обменных нарушений // Современная ревматология. 2018. Т. 12, № 3. С. 82–88. EDN: YOCLTN doi: 10.14412/1996-7012-2018-3-82-88

[19] Bainbridge SA, Roberts JM. Uric acid as a pathogenic factor in preeclampsia. Placenta. 2008;29 Suppl A(Suppl A):S67–72. doi: 10.1016/j.placenta.2007.11.001

[20] Bainbridge S.A., Roberts J.M. Uric acid as a pathogenic factor in preeclampsia // Placenta. 2008. Vol. 29 Suppl A, N Suppl A. P. S67–72. doi: 10.1016/j.placenta.2007.11.001

[21] Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811–1821. doi: 10.1056/NEJMra0800885

[22] Feig D.I., Kang D.H., Johnson R.J. Uric acid and cardiovascular risk // N Engl J Med. 2008. Vol. 359, N 17. P. 1811–1821. doi: 10.1056/NEJMra0800885

[23] Larina VN, Larin VG. Hyperuricemia and chronic heart failure: risk factors and prognostic parallels. Consilium Medicum. 2020;22(5):62–66. EDN: XYOYVY doi: 10.26442/20751753.2020.5.200158

[24] Ларина В.Н., Ларин В.Г. Гиперурикемия и хроническая сердечная недостаточность: факторы риска и прогностические параллели // Consilium Medicum. 2020. Т. 22, № 5. С. 62–66. EDN: XYOYVY doi: 10.26442/20751753.2020.5.200158

[25] Bhole V, Choi JW, Kim SW, et al. Serum uric acid levels and the risk of type 2 diabetes: a prospective study. Am J Med. 2010;123(10):957–961. doi: 10.1016/j.amjmed.2010.03.027

[26] Bhole V., Choi J.W., Kim S.W., et al. Serum uric acid levels and the risk of type 2 diabetes: a prospective study // Am J Med. 2010. Vol. 123, N 10. P. 957–961. doi: 10.1016/j.amjmed.2010.03.027

[27] Johnson RJ, Kivlighn SD, Kim YG, et al. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis. 1999;33(2):225–234. doi: 10.1016/s0272-6386(99)70295-7

[28] Johnson R.J., Kivlighn S.D., Kim Y.G., et al. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease // Am J Kidney Dis. 1999. Vol. 33, N 2. P. 225–234. doi: 10.1016/s0272-6386(99)70295-7

[29] Hirotsu C, Tufik S, Guindalini C, et al. Association between uric acid levels and obstructive sleep apnea syndrome in a large epidemiological sample. PLoS One. 2013;8(6):e66891. doi: 10.1371/journal.pone.0066891

[30] Hirotsu C., Tufik S., Guindalini C., et al. Association between uric acid levels and obstructive sleep apnea syndrome in a large epidemiological sample // PLoS One. 2013. Vol. 8, N 6. P. e66891. doi: 10.1371/journal.pone.0066891

[31] Benn CL, Dua P, Gurrell R, et al. Physiology of hyperuricemia and urate-lowering treatments. Front Med (Lausanne). 2018;5:160. doi: 10.3389/fmed.2018.00160

[32] Benn C.L., Dua P., Gurrell R., et al. Physiology of hyperuricemia and urate-lowering treatments // Front Med (Lausanne). 2018. Vol. 5. P. 160. doi: 10.3389/fmed.2018.00160

[33] Dalbeth N, Choi HK, Joosten LAB, et al. Gout. Nat Rev Dis Primers. 2019;5(1):69. doi: 10.1038/s41572-019-0115-y

[34] Dalbeth N., Choi H.K., Joosten L.A.B., et al. Gout // Nat Rev Dis Primers. 2019. Vol. 5, N 1. P. 69. doi: 10.1038/s41572-019-0115-y

[35] Ichida K, Matsuo H, Takada T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun. 2012;3:764. doi: 10.1038/ncomms1756

[36] Ichida K., Matsuo H., Takada T., et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia // Nat Commun. 2012. Vol. 3. P. 764. doi: 10.1038/ncomms1756

[37] De Becker B, Borghi C, Burnier M, et al. Uric acid and hypertension: a focused review and practical recommendations. J Hypertens. 2019;37(5):878–883. doi: 10.1097/HJH.0000000000001980

[38] De Becker B., Borghi C., Burnier M., et al. Uric acid and hypertension: a focused review and practical recommendations // J Hypertens. 2019. Vol. 37, N 5. P. 878–883. doi: 10.1097/HJH.0000000000001980

[39] Molchanova OV, Britov AN, Platonova EV. Importance of elevated uric acid levels in the development and prevention of chronic non-communicable diseases. Russian Journal of Preventive Medicine. 2020;23(2):102–108. EDN: KJEIBS doi: 10.17116/profmed202023021102

[40] Молчанова О.В., Бритов А.Н., Платонова Е.В. Значение повышенного уровня мочевой кислоты в развитии и профилактике хронических неинфекционных заболеваний // Профилактическая медицина. 2020. Т. 23, № 2. С. 102–108. EDN: KJEIBS doi: 10.17116/profmed202023021102

[41] Borghi C, Domienik-Karłowicz J, Tykarski A, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update. Cardiol J. 2021;28(1):1–14. doi: 10.5603/CJ.a2021.0001

[42] Borghi C., Domienik-Karłowicz J., Tykarski A., et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update // Cardiol J. 2021. Vol. 28, N 1. P. 1–14. doi: 10.5603/CJ.a2021.0001

[43] Virdis A, Masi S, Casiglia E, et al. Identification of the uric acid thresholds predicting an increased total and cardiovascular mortality over 20 years. Hypertension. 2020;75(2):302–308. doi: 10.1161/HYPERTENSIONAHA.119.13643

[44] Virdis A., Masi S., Casiglia E., et al. Identification of the uric acid thresholds predicting an increased total and cardiovascular mortality over 20 years // Hypertension. 2020. Vol. 75, N 2. P. 302–308. doi: 10.1161/HYPERTENSIONAHA.119.13643

[45] Kim YG, Huang XR, Suga S, et al. Involvement of macrophage migration inhibitory factor (MIF) in experimental uric acid nephropathy. Mol Med. 2000;6(10):837–848.

[46] Kim Y.G., Huang X.R., Suga S., et al. Involvement of macrophage migration inhibitory factor (MIF) in experimental uric acid nephropathy // Mol Med. 2000. Vol. 6, N 10. P. 837–848.

[47] Barazani SH, Chi WW, Pyzik R, et al. Quantification of uric acid in vasculature of patients with gout using dual-energy computed tomography. World J Radiol. 2020;12(8):184–194. doi: 10.4329/wjr.v12.i8.184

[48] Barazani S.H., Chi W.W., Pyzik R., et al. Quantification of uric acid in vasculature of patients with gout using dual-energy computed tomography // World J Radiol. 2020. Vol. 12, N 8. P. 184–194. doi: 10.4329/wjr.v12.i8.184

[49] Ruggiero C, Cherubini A, Ble A, et al. Uric acid and inflammatory markers. Eur Heart J. 2006;27(10):1174–1181. doi: 10.1093/eurheartj/ehi879

[50] Ruggiero C., Cherubini A., Ble A., et al. Uric acid and inflammatory markers // Eur Heart J. 2006. Vol. 27, N 10. P. 1174–1181. doi: 10.1093/eurheartj/ehi879

[51] Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012;125(7):679–687.e1. doi: 10.1016/j.amjmed.2011.09.033

[52] Zhu Y., Pandya B.J., Choi H.K. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008 // Am J Med. 2012. Vol. 125, N 7. P. 679–687.e1. doi: 10.1016/j.amjmed.2011.09.033

[53] Maloberti A, Biolcati M, Ruzzenenti G, et al. The role of uric acid in acute and chronic coronary syndromes. J Clin Med. 2021;10(20):4750. doi: 10.3390/jcm10204750

[54] Maloberti A., Biolcati M., Ruzzenenti G., et al. The role of uric acid in acute and chronic coronary syndromes // J Clin Med. 2021. Vol. 10, N 20. P. 4750. doi: 10.3390/jcm10204750

[55] Feig DI, Madero M, Jalal DI, et al. Uric acid and the origins of hypertension. J Pediatr. 2013;162(5):896–902. doi: 10.1016/j.jpeds.2012.12.078

[56] Feig D.I., Madero M., Jalal D.I., et al. Uric acid and the origins of hypertension // J Pediatr. 2013. Vol. 162, N 5. P. 896–902. doi: 10.1016/j.jpeds.2012.12.078

[57] Wheeler JG, Juzwishin KD, Eiriksdottir G, et al. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med. 2005;2(3):e76. doi: 10.1371/journal.pmed.0020076

[58] Wheeler J.G., Juzwishin K.D., Eiriksdottir G., et al. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis // PLoS Med. 2005. Vol. 2, N 3. P. e76. doi: 10.1371/journal.pmed.0020076

[59] Yan L, Liu Z, Zhang C. Uric acid as a predictor of in-hospital mortality in acute myocardial infarction: a meta-analysis. Cell Biochem Biophys. 2014;70(3):1597–1601. doi: 10.1007/s12013-014-0101-7

[60] Yan L., Liu Z., Zhang C. Uric acid as a predictor of in-hospital mortality in acute myocardial infarction: a meta-analysis // Cell Biochem Biophys. 2014. Vol. 70, N 3. P. 1597–1601. doi: 10.1007/s12013-014-0101-7

[61] Leyva F, Anker S, Swan JW, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997;18(5):858–865. doi: 10.1093/oxfordjournals.eurheartj.a015352

[62] Leyva F., Anker S., Swan J.W., et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure // Eur Heart J. 1997. Vol. 18, N 5. P. 858–865. doi: 10.1093/oxfordjournals.eurheartj.a015352

[63] Tamariz L, Harzand A, Palacio A, et al. Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis. Congest Heart Fail. 2011;17(1):25–30. doi: 10.1111/j.1751-7133.2011.00200.x

[64] Tamariz L., Harzand A., Palacio A., et al. Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis // Congest Heart Fail. 2011. Vol. 17, N 1. P. 25–30. doi: 10.1111/j.1751-7133.2011.00200.x

[65] Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104. doi: 10.1093/eurheartj/ehy339

[66] Williams B., Mancia G., Spiering W., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension // Eur Heart J. 2018. Vol. 39, N 33. P. 3021–3104. doi: 10.1093/eurheartj/ehy339

[67] Kobalava ZD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):149–218. EDN: TCRBRB doi: 10.15829/1560-4071-2020-3-3786

[68] Кобалава Ж.Д., Конради А.О., Недогода С.В., и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020 // Российский кардиологический журнал. 2020. Т. 25, № 3. С. 149–218. EDN: TCRBRB doi: 10.15829/1560-4071-2020-3-3786

[69] Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–3337. doi: 10.1093/eurheartj/ehab484

[70] Visseren F.L.J., Mach F., Smulders Y.M., et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice // Eur Heart J. 2021. Vol. 42, N 34. P. 3227–3337. doi: 10.1093/eurheartj/ehab484

[71] Grayson PC, Kim SY, LaValley M, et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63(1):102–110. doi: 10.1002/acr.20344

[72] Grayson P.C., Kim S.Y., LaValley M., et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis // Arthritis Care Res (Hoboken). 2011. Vol. 63, N 1. P. 102–110. doi: 10.1002/acr.20344

[73] Cicero AF, Salvi P, D’Addato S, et al. Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study. J Hypertens. 2014;32(1):57–64. doi: 10.1097/HJH.0b013e328365b916

[74] Cicero A.F., Salvi P., D’Addato S., et al. Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study // J Hypertens. 2014. Vol. 32, N 1. P. 57–64. doi: 10.1097/HJH.0b013e328365b916

[75] White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200–1210. doi: 10.1056/NEJMoa1710895

[76] White W.B., Saag K.G., Becker M.A., et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout // N Engl J Med. 2018. Vol. 378, N 13. P. 1200–1210. doi: 10.1056/NEJMoa1710895

[77] Choi H, Neogi T, Stamp L, et al. New Perspectives in rheumatology: implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial and the associated food and drug administration public safety alert. Arthritis Rheumatol. 2018;70(11):1702–1709. doi: 10.1002/art.40583

[78] Choi H., Neogi T., Stamp L., et al. New Perspectives in rheumatology: implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial and the associated food and drug administration public safety alert // Arthritis Rheumatol. 2018. Vol. 70, N 11. P. 1702–1709. doi: 10.1002/art.40583

[79] MacIsaac RL, Salatzki J, Higgins P, et al. Allopurinol and cardiovascular outcomes in adults with hypertension. Hypertension. 2016;67(3):535–540. doi: 10.1161/HYPERTENSIONAHA.115.06344

[80] MacIsaac R.L., Salatzki J., Higgins P., et al. Allopurinol and cardiovascular outcomes in adults with hypertension // Hypertension. 2016. Vol. 67, N 3. P. 535–540. doi: 10.1161/HYPERTENSIONAHA.115.06344

[81] Bickel C, Rupprecht HJ, Blankenberg S, et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol. 2002;89(1):12–17. doi: 10.1016/s0002-9149(01)02155-5

[82] Bickel C., Rupprecht H.J., Blankenberg S., et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease // Am J Cardiol. 2002. Vol. 89, N 1. P. 12–17. doi: 10.1016/s0002-9149(01)02155-5

[83] Mackenzie IS, Ford I, Walker A, et al. Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study. BMJ Open. 2016;6(9):e013774. doi: 10.1136/bmjopen-2016-013774

[84] Mackenzie I.S., Ford I., Walker A., et al. Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study // BMJ Open. 2016. Vol. 6, N 9. P. e013774. doi: 10.1136/bmjopen-2016-013774

[85] Mackenzie IS, Hawkey CJ, Ford I, et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400(10359):1195–1205. doi: 10.1016/S0140-6736(22)01657-9

[86] Mackenzie I.S., Hawkey C.J., Ford I., et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial // Lancet. 2022. Vol. 400, N 10359. P. 1195–1205. doi: 10.1016/S0140-6736(22)01657-9

[87] Perez-Gomez MV, Bartsch LA, Castillo-Rodriguez E, et al. Potential dangers of serum urate-lowering therapy. Am J Med. 2019;132(4):457–467. doi: 10.1016/j.amjmed.2018.12.010

[88] Perez-Gomez M.V., Bartsch L.A., Castillo-Rodriguez E., et al. Potential dangers of serum urate-lowering therapy // Am J Med. 2019. Vol. 132, N 4. P. 457–467. doi: 10.1016/j.amjmed.2018.12.010

[89] Palazzuoli A, Ruocco G, De Vivo O, et al. Prevalence of hyperuricemia in patients with acute heart failure with either reduced or preserved ejection fraction. Am J Cardiol. 2017;120(7):1146–1150. doi: 10.1016/j.amjcard.2017.06.057

[90] Palazzuoli A., Ruocco G., De Vivo O., et al. Prevalence of hyperuricemia in patients with acute heart failure with either reduced or preserved ejection fraction // Am J Cardiol. 2017. Vol. 120, N 7. P. 1146–1150. doi: 10.1016/j.amjcard.2017.06.057

[91] Doehner W, Rauchhaus M, Florea VG, et al. Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance. Am Heart J. 2001;141(5):792–799. doi: 10.1067/mhj.2001.114367

[92] Doehner W., Rauchhaus M., Florea V.G., et al. Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance // Am Heart J. 2001. Vol. 141, N 5. P. 792–799. doi: 10.1067/mhj.2001.114367

[93] Nishino M, Egami Y, Kawanami S, et al. Lowering uric acid may improve prognosis in patients with hyperuricemia and heart failure with preserved ejection fraction. J Am Heart Assoc. 2022;11(19):e026301. doi: 10.1161/JAHA.122.026301

[94] Nishino M., Egami Y., Kawanami S., et al. Lowering uric acid may improve prognosis in patients with hyperuricemia and heart failure with preserved ejection fraction // J Am Heart Assoc. 2022. Vol. 11, N 19. P. e026301. doi: 10.1161/JAHA.122.026301

[95] Beattie CJ, Fulton RL, Higgins P, et al. Allopurinol initiation and change in blood pressure in older adults with hypertension. Hypertension. 2014;64(5):1102–1107. doi: 10.1161/HYPERTENSIONAHA.114.03953

[96] Beattie C.J., Fulton R.L., Higgins P., et al. Allopurinol initiation and change in blood pressure in older adults with hypertension // Hypertension. 2014. Vol. 64, N 5. P. 1102–1107. doi: 10.1161/HYPERTENSIONAHA.114.03953

[97] Dubreuil M, Zhu Y, Zhang Y, et al. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis. 2015;74(7):1368–1372. doi: 10.1136/annrheumdis-2014-205269

[98] Dubreuil M., Zhu Y., Zhang Y., et al. Allopurinol initiation and all-cause mortality in the general population // Ann Rheum Dis. 2015. Vol. 74, N 7. P. 1368–1372. doi: 10.1136/annrheumdis-2014-205269

[99] Wei L, Fahey T, Struthers AD, et al. Association between allopurinol and mortality in heart failure patients: a long-term follow-up study. Int J Clin Pract. 2009;63(9):1327–1333. doi: 10.1111/j.1742-1241.2009.02118.x

[100] Wei L., Fahey T., Struthers A.D., et al. Association between allopurinol and mortality in heart failure patients: a long-term follow-up study // Int J Clin Pract. 2009. Vol. 63, N 9. P. 1327–1333. doi: 10.1111/j.1742-1241.2009.02118.x

[101] Li L, Yang C, Zhao Y, et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014;15:122. doi: 10.1186/1471-2369-15-122

[102] Li L., Yang C., Zhao Y., et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies // BMC Nephrol. 2014. Vol. 15. P. 122. doi: 10.1186/1471-2369-15-122

[103] Madero M, Sarnak MJ, Wang X, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009;53(5):796–803. doi: 10.1053/j.ajkd.2008.12.021

[104] Madero M., Sarnak M.J., Wang X., et al. Uric acid and long-term outcomes in CKD // Am J Kidney Dis. 2009. Vol. 53, N 5. P. 796–803. doi: 10.1053/j.ajkd.2008.12.021

[105] Collins AJ, Li S, Gilbertson DT, et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl. 2003;(87):S24–31. doi: 10.1046/j.1523-1755.64.s87.5.x

[106] Collins A.J., Li S., Gilbertson D.T., et al. Chronic kidney disease and cardiovascular disease in the Medicare population // Kidney Int Suppl. 2003. N 87. P. S24–31. doi: 10.1046/j.1523-1755.64.s87.5.x

[107] Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305. doi: 10.1056/NEJMoa041031

[108] Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization // N Engl J Med. 2004. Vol. 351, N 13. P. 1296–1305. doi: 10.1056/NEJMoa041031

[109] Oh CM, Park SK, Ryoo JH. Serum uric acid level is associated with the development of microalbuminuria in Korean men. Eur J Clin Invest. 2014;44(1):4–12. doi: 10.1111/eci.12180

[110] Oh C.M., Park S.K., Ryoo J.H. Serum uric acid level is associated with the development of microalbuminuria in Korean men // Eur J Clin Invest. 2014. Vol. 44, N 1. P. 4–12. doi: 10.1111/eci.12180

[111] Uchida S, Chang WX, Ota T, et al. Targeting uric acid and the inhibition of progression to end-stage renal disease–a propensity score analysis. PLoS One. 2015;10(12):e0145506. doi: 10.1371/journal.pone.0145506

[112] Uchida S., Chang W.X., Ota T., et al. Targeting uric acid and the inhibition of progression to end-stage renal disease–a propensity score analysis // PLoS One. 2015. Vol. 10, N 12. P. e0145506. doi: 10.1371/journal.pone.0145506

[113] Sharma G, Dubey A, Nolkha N, et al. Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis. Ther Adv Musculoskelet Dis. 2021;13:1759720X211016661. doi: 10.1177/1759720X211016661

[114] Sharma G., Dubey A., Nolkha N., et al. Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis // Ther Adv Musculoskelet Dis. 2021. Vol. 13. P. 1759720X211016661. doi: 10.1177/1759720X211016661

[115] Eliseev MS, Chikina MN, Zhelyabina OV. Open 6-month study on the efficacy of dose titration of allopurinol in patients with gout as part of the “treat to target” strategy. RMJ. 2022;(6):17–22. EDN: LLFCTA

[116] Елисеев М.С., Чикина М.Н., Желябина О.В. Открытое 6-месячное исследование эффективности титрования дозы аллопуринола у пациентов с подагрой в рамках стратегии «лечение до цели» // РМЖ. 2022. № 6. С. 17–22. EDN: LLFCTA

[117] Mazurov VI, Sayganov SА, Martynov AI, et al. Impact of urate-lowering therapy on the course of chronic kidney disease in patients with asymptomatic hyperuricemia: a meta-analysis of randomized controlled trials. I.I. Mechnikov Herald of North-Western State Medical University. 2023;15(4):5–18. EDN: ESRPKU doi: 10.17816/mechnikov604850

[118] Мазуров В.И., Сайганов С.А., Мартынов А.И., и др. Влияние уратснижающей терапии на течение хронической болезни почек у пациентов с бессимптомной гиперурикемией: метаанализ рандомизированных контролируемых исследований // Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2023. Т. 15, № 4. С. 5–18. EDN: ESRPKU doi: 10.17816/mechnikov604850

[119] Mazurov VI, Drapkina OM, Martynov АI, et al. Meta-analysis of observational cohort studies on the relationships of asymptomatic hyperuricemia with chronic kidney disease. Therapy. 2023;9(10):21–39. EDN: MWVPUQ doi: 10.18565/therapy.2023.10.21-39

[120] Мазуров В.И., Драпкина О.М., Мартынов А.И., и др. Метаанализ наблюдательных когортных исследований о взаимосвязях бессимптомной гиперурикемии с хронической болезнью почек // Терапия. 2023. Т. 9, № 10. С. 21–39. EDN: MWVPUQ doi: 10.18565/therapy.2023.10.21-39

[121] Shi Y, Chen W, Jalal D, et al. Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney Blood Press Res. 2012;35(3):153–160. doi: 10.1159/000331453

[122] Shi Y., Chen W., Jalal D., et al. Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial // Kidney Blood Press Res. 2012. Vol. 35, N 3. P. 153–160. doi: 10.1159/000331453

[123] Kimura K, Hosoya T, Uchida S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis. 2018;72(6):798–810. doi: 10.1053/j.ajkd.2018.06.028

[124] Kimura K., Hosoya T., Uchida S., et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial // Am J Kidney Dis. 2018. Vol. 72, N 6. P. 798–810. doi: 10.1053/j.ajkd.2018.06.028

[125] Nagano S, Takahashi M, Miyai N, et al. Association of serum uric acid with subsequent arterial stiffness and renal function in normotensive subjects. Hypertens Res. 2017;40(6):620–624. doi: 10.1038/hr.2017.10

[126] Nagano S., Takahashi M., Miyai N., et al. Association of serum uric acid with subsequent arterial stiffness and renal function in normotensive subjects // Hypertens Res. 2017. Vol. 40, N 6. P. 620–624. doi: 10.1038/hr.2017.10

[127] Wang S, Shu Z, Tao Q, et al. Uric acid and incident chronic kidney disease in a large health check-up population in Taiwan. Nephrology (Carlton). 2011;16(8):767–776. doi: 10.1111/j.1440-1797.2011.01513

[128] Wang S., Shu Z., Tao Q., et al. Uric acid and incident chronic kidney disease in a large health check-up population in Taiwan // Nephrology (Carlton). 2011. Vol. 16, N 8. P. 767–776. doi: 10.1111/j.1440-1797.2011.01513

[129] Mazurov VI, Gaydukova IZ, Cinzerling AY, et al. Effect of asymptomatic hyperuricemia on the incidence and pattern of comorbid pathology in rheumatoid arthritis. Therapy. 2022;8(6):27–33. EDN: NNQMCS doi: 10.18565/therapy.2022.6.27-33

[130] Мазуров В.И., Гайдукова И.З., Цинзерлинг А.Ю., и др. Влияние бессимптомной гиперурикемии на частоту и структуру коморбидной патологии при ревматоидном артрите // Терапия. 2022. Т. 8, № 6. С. 27–33. EDN: NNQMCS doi: 10.18565/therapy.2022.6.27-33

[131] Mazurov VI, Gaidukova IZ, Bashkinov RA, et al. Asymptomatic hyperuricemia impact on the comorbid pathology course in patients with osteoarthritis and the possibility of its correction. RMJ. 2021;29(6):56–62. EDN: GDWNGZ

[132] Мазуров В.И., Гайдукова И.З., Башкинов Р.А., и др. Влияние бессимптомной гиперурикемии на течение коморбидной патологии у пациентов с остеоартритом и возможности ее коррекции // РМЖ. 2021. Т. 29, № 6. С. 56–62. EDN: GDWNGZ

[133] Mazurov VI, Sayganov SA, Bashkinov RA, et al. Effect of urate-lowering therapy on the progression of chronic kidney disease in patients with osteoarthritis and asymptomatic hyperuricemia. Therapy. 2023;9(7):56–71. EDN: RDYJFA doi: 10.18565/therapy.2023.7.56-71

[134] Мазуров В.И., Сайганов С.А., Башкинов Р.А. и др. Влияние уратснижающей терапии на течение хронической болезни почек у пациентов с остеоартритом и бессимптомной гиперурикемией // Терапия. 2023. Т. 9, № 7. С. 56–71. EDN: RDYJFA doi: 10.18565/therapy.2023.7.56-71

[135] Tsinserling AYu, Mazurov VI, Gaydukova IZ, et al. Asymptomatic hyperuricemia and radiographic progression of rheumatoid arthritis. Russian Medical Inquiry. 2022;6(8):470–479. EDN: UNBZWA doi: 10.32364/2587-6821-2022-6-8-470-479

[136] Цинзерлинг А.Ю., Мазуров В.И., Гайдукова И.З., и др. Бессимптомная гиперурикемия и рентгенологическое прогрессирование ревматоидного артрита // РМЖ. Медицинское обозрение. 2022. Т. 6, № 8. С. 470–479. EDN: UNBZWA doi: 10.32364/2587-6821-2022-6-8-470-479

[137] Li Q, Li X, Wang J, et al. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements. BMJ Open. 2019;9(8):e026677. doi: 10.1136/bmjopen-2018-026677

[138] Li Q., Li X., Wang J., et al. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements // BMJ Open. 2019. Vol. 9, N 8. P. e026677. doi: 10.1136/bmjopen-2018-026677

[139] Hisatome I, Kimiyoshi I, Mineo I, et al. Japanese Society of Gout and Uric and Nucleic Acids 2019 Guidelines for Management of Hyperuricemia and Gout 3rd edition. Gout and Uric and Nucleic Acids. 2020;44:1–40. doi: 10.14867/gnamtsunyo.44.Supplement_sp-1

[140] Hisatome I., Kimiyoshi I., Mineo I., et al. Japanese Society of Gout and Uric & Nucleic Acids 2019 Guidelines for Management of Hyperuricemia and Gout 3rd edition // Gout and Uric & Nucleic Acids. 2020. Vol. 44. P. 1–40. doi: 10.14867/gnamtsunyo.44.Supplement_sp-1

[141] Chinese Society of Endocrinology. Guideline for the Diagnosis and Management of Hyperuricemia and Gout in China (2019). Chin J Endocrinol Metab. 2020;36(1):1–13. doi: 10.3760/cma.j.issn.1000-6699.2020.01.001

[142] Chinese Society of Endocrinology. Guideline for the Diagnosis and Management of Hyperuricemia and Gout in China (2019) // Chin J Endocrinol Metab. 2020. Vol. 36, N 1. P. 1–13. doi: 10.3760/cma.j.issn.1000-6699.2020.01.001

[143] Pisano A, Cernaro V, Gembillo G, et al. Xanthine oxidase inhibitors for improving renal function in chronic kidney disease patients: an updated systematic review and meta-analysis. Int J Mol Sci. 2017;18(11):2283. doi: 10.3390/ijms18112283

[144] Pisano A., Cernaro V., Gembillo G., et al. Xanthine oxidase inhibitors for improving renal function in chronic kidney disease patients: an updated systematic review and meta-analysis // Int J Mol Sci. 2017. Vol. 18, N 11. P. 2283. doi: 10.3390/ijms18112283

[145] Su X, Xu B, Yan B, et al. Effects of uric acid-lowering therapy in patients with chronic kidney disease: A meta-analysis. PLoS One. 2017;12(11):e0187550. doi: 10.1371/journal.pone.0187550

[146] Su X., Xu B., Yan B., et al. Effects of uric acid-lowering therapy in patients with chronic kidney disease: A meta-analysis // PLoS One. 2017. Vol. 12, N 11. P. e0187550. doi: 10.1371/journal.pone.0187550

[147] Luo Q, Cai Y, Zhao Q, et al. Effects of allopurinol on renal function in patients with diabetes: a systematic review and meta-analysis. Ren Fail. 2022;44(1):806–814. doi: 10.1080/0886022X.2022.2068443

[148] Luo Q., Cai Y., Zhao Q., et al. Effects of allopurinol on renal function in patients with diabetes: a systematic review and meta-analysis // Ren Fail. 2022. Vol. 44, N 1. P. 806–814. doi: 10.1080/0886022X.2022.2068443

[149] Mazurov VI, Trofimov EA, Samigullina RR. Rheumatoid arthritis. In: Mazurov VI, editor. Clinical rheumatology. A guide for doctors. Third ed. Moscow: E-noto; 2021. P. 72–105. (In Russ.)

[150] Мазуров В.И., Трофимов Е.А., Самигуллина Р.Р. Ревматоидный артрит. В кн.: Клиническая ревматология. Руководство для врачей / под ред. В.И. Мазурова. 3-е изд. Москва: Е-ното, 2021. С. 72–105.

[151] Mazurov VI, Gaydukova IZ, Fonturenko AYu, et al. Coexistent rheumatoid arthritis and hyperuricemia: clinical and immunological features. Herald of North-Western State Medical University named after I.I. Mechnikov. 2021;13(3):43–52. EDN: OSUZME doi: 10.17816/mechnikov80731

[152] Мазуров В.И., Гайдукова И.З., Фонтуренко А.Ю., и др. Клинико-иммунологические особенности сочетанного течения ревматоидного артрита и гиперурикемии // Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2021. Т. 13, № 3. С. 43–52. EDN: OSUZME doi: 10.17816/mechnikov80731

[153] Panoulas VF, Milionis HJ, Douglas KM, et al. Association of serum uric acid with cardiovascular disease in rheumatoid arthritis. Rheumatology (Oxford). 2007;46(9):1466–1470. doi: 10.1093/rheumatology/kem159

[154] Panoulas V.F., Milionis H.J., Douglas K.M., et al. Association of serum uric acid with cardiovascular disease in rheumatoid arthritis // Rheumatology (Oxford). 2007. Vol. 46, N 9. P. 1466–1470. doi: 10.1093/rheumatology/kem159

[155] Chiou A, England BR, Sayles H, et al. Coexistent hyperuricemia and gout in rheumatoid arthritis: associations with comorbidities, disease activity, and mortality. Arthritis Care Res (Hoboken). 2020;72(7):950–958. doi: 10.1002/acr.23926

[156] Chiou A., England B.R., Sayles H., et al. Coexistent hyperuricemia and gout in rheumatoid arthritis: associations with comorbidities, disease activity, and mortality // Arthritis Care Res (Hoboken). 2020. Vol. 72, N 7. P. 950–958. doi: 10.1002/acr.23926

[157] Lila AM, Raimuev KV. Osteoarthritis. In: Mazurov VI, editor. Clinical rheumatology. A guide for doctors. 3rd edition. Moscow: E-noto; 2021. P. 105–126. (In Russ.)

[158] Лила А.М., Раймуев К.В. Остеоартрит. В кн.: Клиническая ревматология. Руководство для врачей / под ред. В.И. Мазурова. 3-е изд. Москва: Е-ното, 2021. С. 105–126.

[159] Bashkinov RA, Mazurov VI, Gaydukova IZ, et al. Features of the course of osteoarthritis in patients with asymptomatic hyperuricemia. Therapy. 2025;11(1):16–28. EDN: AAFGTW doi: 10.18565/therapy.2025.1.16-28

[160] Башкинов Р.А., Мазуров В.И., Гайдукова И.З., и др. Особенности течения остеоартрита у пациентов с бессимптомной гиперурикемией // Терапия. 2025. Т. 11, № 1. С. 16–28. EDN: AAFGTW doi: 10.18565/therapy.2025.1.16-28

[161] Cheremushkina EV, Eliseev MS. Hyperuricemia and gout: effects on bone and articular cartilage (literature review). Obesity and metabolism. 2022;19(3):348–357. EDN: ZNSHBH doi: 10.14341/omet12894

[162] Черёмушкина Е.В., Елисеев М.С. Гиперурикемия и подагра: влияние на костный метаболизм и суставной хрящ (обзор литературы) // Ожирение и метаболизм. 2022. Т. 19, № 3. С. 348–357. EDN: ZNSHBH doi: 10.14341/omet12894

[163] Cheremushkina EV, Eliseev MS, Severinova MV, Zhelyabina OV. Sonography as method for diagnosing gout at preclinical stage (preliminary data from pilot study). Medical alphabet. 2023;(9):30–34. EDN: SMDPLS doi: 10.33667/2078-5631-2023-9-30-34

[164] Черемушкина Е.В., Елисеев М.С., Северинова М.В., Желябина О.В. Сонография как метод диагностики подагры на преклинической стадии (предварительные данные пилотного исследования) // Медицинский алфавит. 2023. № 9. С. 30–34. EDN: SMDPLS doi: 10.33667/2078-5631-2023-9-30-34

[165] Tripolino C, Ciaffi J, Ruscitti P, et al. Hyperuricemia in psoriatic arthritis: epidemiology, pathophysiology, and clinical implications. Front Med (Lausanne). 2021;8:737573. doi: 10.3389/fmed.2021.737573

[166] Tripolino C., Ciaffi J., Ruscitti P., et al. Hyperuricemia in psoriatic arthritis: epidemiology, pathophysiology, and clinical implications // Front Med (Lausanne). 2021. Vol. 8. P. 737573. doi: 10.3389/fmed.2021.737573

[167] Felten R, Duret PM, Gottenberg JE, et al. At the crossroads of gout and psoriatic arthritis: “psout”. Clin Rheumatol. 2020;39(5):1405–1413. doi: 10.1007/s10067-020-04981-0

[168] Felten R., Duret P.M., Gottenberg J.E., et al. At the crossroads of gout and psoriatic arthritis: “psout” // Clin Rheumatol. 2020. Vol. 39, N 5. P. 1405–1413. doi: 10.1007/s10067-020-04981-0

[169] Krishnan E, Pandya BJ, Chung L, et al. Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15-year follow-up study. Am J Epidemiol. 2012;176(2):108–116. doi: 10.1093/aje/kws002

[170] Krishnan E., Pandya B.J., Chung L., et al. Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15-year follow-up study // Am J Epidemiol. 2012. Vol. 176, N 2. P. 108–116. doi: 10.1093/aje/kws002

[171] Bombelli M, Quarti-Trevano F, Tadic M, et al. Uric acid and risk of new-onset metabolic syndrome, impaired fasting glucose and diabetes mellitus in a general Italian population: data from the Pressioni Arteriose Monitorate E Loro Associazioni study. J Hypertens. 2018;36(7):1492–1498. doi: 10.1097/HJH.0000000000001721

[172] Bombelli M., Quarti-Trevano F., Tadic M., et al. Uric acid and risk of new-onset metabolic syndrome, impaired fasting glucose and diabetes mellitus in a general Italian population: data from the Pressioni Arteriose Monitorate E Loro Associazioni study // J Hypertens. 2018. Vol. 36, N 7. P. 1492–1498. doi: 10.1097/HJH.0000000000001721

[173] Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009;32(9):1737–1742. doi: 10.2337/dc09-0288

[174] Kodama S., Saito K., Yachi Y., et al. Association between serum uric acid and development of type 2 diabetes // Diabetes Care. 2009. Vol. 32, N 9. P. 1737–1742. doi: 10.2337/dc09-0288

[175] Lv Q, Meng XF, He FF, et al. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS One. 2013;8(2):e56864. doi: 10.1371/journal.pone.0056864

[176] Lv Q., Meng X.F., He F.F., et al. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies // PLoS One. 2013. Vol. 8, N 2. P. e56864. doi: 10.1371/journal.pone.0056864

[177] Xu Y, Zhu J, Gao L, et al. Hyperuricemia as an independent predictor of vascular complications and mortality in type 2 diabetes patients: a meta-analysis. PLoS One. 2013;8(10):e78206. doi: 10.1371/journal.pone.0078206

[178] Xu Y., Zhu J., Gao L., et al. Hyperuricemia as an independent predictor of vascular complications and mortality in type 2 diabetes patients: a meta-analysis // PLoS One. 2013. Vol. 8. N 10. P. e78206. doi: 10.1371/journal.pone.0078206

[179] Yu S, Chen Y, Hou X, et al. Serum uric acid levels and diabetic peripheral neuropathy in type 2 diabetes: a systematic review and meta-analysis. Mol Neurobiol. 2016;53(2):1045–1051. doi: 10.1007/s12035-014-9075-0

[180] Yu S., Chen Y., Hou X., et al. Serum uric acid levels and diabetic peripheral neuropathy in type 2 diabetes: a systematic review and meta-analysis // Mol Neurobiol. 2016. Vol. 53, No. 2. P. 1045–1051. doi: 10.1007/s12035-014-9075-0

[181] Guo Y, Liu S, Xu H. Uric acid and diabetic retinopathy: a systematic review and meta-analysis. Front Public Health. 2022;10:906760. doi: 10.3389/fpubh.2022.906760

[182] Guo Y., Liu S., Xu H. Uric acid and diabetic retinopathy: a systematic review and meta-analysis // Front Public Health. 2022. Vol. 10. P. 906760. doi: 10.3389/fpubh.2022.906760

[183] Lee JJ, Yang IH, Kuo HK, et al. Serum uric acid concentration is associated with worsening in severity of diabetic retinopathy among type 2 diabetic patients in Taiwan – a 3-year prospective study. Diabetes Res Clin Pract. 2014;106(2):366–372. doi: 10.1016/j.diabres.2014.07.027

[184] Lee J.J., Yang I.H., Kuo H.K., et al. Serum uric acid concentration is associated with worsening in severity of diabetic retinopathy among type 2 diabetic patients in Taiwan – a 3-year prospective study // Diabetes Res Clin Pract. 2014. Vol. 106, N 2. P. 366–372. doi: 10.1016/j.diabres.2014.07.027

[185] Zoppini G, Targher G, Chonchol M, et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care. 2012;35(1):99–104. doi: 10.2337/dc11-1346

[186] Zoppini G., Targher G., Chonchol M., et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function // Diabetes Care. 2012. Vol. 35, N 1. P. 99–104. doi: 10.2337/dc11-1346

[187] Chang YH, Lei CC, Lin KC, et al. Serum uric acid level as an indicator for CKD regression and progression in patients with type 2 diabetes mellitus-a 4.6-year cohort study. Diabetes Metab Res Rev. 2016;32(6):557–564. doi: 10.1002/dmrr.2768

[188] Chang Y.H., Lei C.C., Lin K.C., et al. Serum uric acid level as an indicator for CKD regression and progression in patients with type 2 diabetes mellitus-a 4.6-year cohort study // Diabetes Metab Res Rev. 2016. Vol. 32, N 6. P. 557–564. doi: 10.1002/dmrr.2768

[189] Panevin TS, Salukhov VV, Reut DM. Rational choice of therapy in patients with diabetes mellitus type 2 with concomitant gout. Medical Council. 2023;17(9):96–103. EDN: SASXVX doi: 10.21518/ms2023-153

[190] Паневин Т.С., Салухов В.В., Реут Д.М. Рациональный выбор терапии у больных сахарным диабетом 2-го типа при сопутствующей подагре // Медицинский Совет. 2023. Т. 17, № 9. С. 96–103. EDN: SASXVX doi: 10.21518/ms2023-153

[191] Yip ASY, Leong S, Teo YH, et al. Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials. Ther Adv Chronic Dis. 2022;13:20406223221083509. doi: 10.1177/20406223221083509

[192] Yip A.S.Y., Leong S., Teo Y.H., et al. Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials // Ther Adv Chronic Dis. 2022. Vol. 13. P. 20406223221083509. doi: 10.1177/20406223221083509

[193] Zheliabina OV, Eliseev MS, Glukhova SI, Nasonov EL. Contributing factors of diabetes mellitus among patients with gout (results of the long-term prospective study). Rheumatology Science and Practice. 2022;60(3):374–380. EDN: AZIZHM doi: 10.47360/1995-4484-2022-374-380

[194] Желябина О.В., Елисеев М.С., Глухова С.И., Насонов Е.Л. Факторы, влияющие на развитие сахарного диабета 2-го типа у пациентов с подагрой (результаты многолетнего проспективного исследования) // Научно-практическая ревматология. 2022. Т. 60, № 3. С. 374–380. EDN: AZIZHM doi: 10.47360/1995-4484-2022-374-380

[195] Zhelyabina OV, Eliseev MS, Glukhova SI, et al. Risk factors for type 2 diabetes mellitus in patients with gout: results from a prospective study. Modern Rheumatology Journal. 2022;16(1):52–59. EDN: STYMQH doi: 10.14412/1996-7012-2022-1-52-59

[196] Желябина О.В., Елисеев М.С., Глухова С.И., и др. Факторы риска развития сахарного диабета 2-го типа у пациентов с подагрой: результаты проспективного исследования // Современная ревматология. 2022. Т. 16, № 1. С. 52–59. EDN: STYMQH doi: 10.14412/1996-7012-2022-1-52-59

[197] Chazova IE, Zhernakova JuV, Kisliak OA, et al. Consensus on patients with hyperuricemia and high cardiovascular risk treatment. Systemic Hypertension. 2019;16(4):8–21. EDN: HSKPCZ doi: 10.26442/2075082X.2019.4.190686

[198] Чазова И.Е., Жернакова Ю.В., Кисляк О.А., и др. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском // Системные гипертензии. 2019. Т. 16, № 4. С. 8–21. EDN: HSKPCZ doi: 10.26442/2075082X.2019.4.190686

[199] Borghi C, Tykarski A, Widecka K, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiol J. 2018;25(5):545–563. doi: 10.5603/CJ.2018.0116

[200] Borghi C., Tykarski A., Widecka K., et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk // Cardiol J. 2018. Vol. 25, N 5. P. 545–563. doi: 10.5603/CJ.2018.0116

RIGHTS & PERMISSIONS

Eco-Vector